Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10072900 | 0.82 | HSD11B1 (0.52) | HSD11B1 | |
| SCHEMBL10072911 | 0.69 | UTS2R (0.39) | — | |
| SCHEMBL12243475 | 0.68 | MET (0.39) | — | |
| SCHEMBL10072893 | 0.68 | ALDH1A1 (0.41) | — | |
| SCHEMBL10073655 | 0.68 | ALDH1A1 (0.50) | — | |
| SCHEMBL10073657 | 0.67 | NAMPT (0.38) | — | |
| SCHEMBL10073159 | 0.67 | ALDH1A1 (0.35) | — | |
| SCHEMBL10073648 | 0.67 | ALDH1A1 (0.42) | — | |
| SCHEMBL10073647 | 0.67 | ALDH1A1 (0.47) | — | |
| SCHEMBL10072908 | 0.67 | L3MBTL1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2514751-A1 | Azaindazoles useful as inhibitor of kinases | Vertex Pharmaceuticals, Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120165367-A1 | AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-28 | — | — | US | disclosed |
| WO-2007059219-A1 | AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165367-A1 | AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES | PRKDC, MAP3K20, PRKACA | HSD11B1 2810/4885HTR5A 3469/4885OPRM1 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.